nodes	percent_of_prediction	percent_of_DWPC	metapath
Rosiglitazone—PPARG—psoriasis	0.393	1	CbGaD
Rosiglitazone—CYP2A6—Methoxsalen—psoriasis	0.0459	0.101	CbGbCtD
Rosiglitazone—ALB—Acitretin—psoriasis	0.0359	0.0791	CbGbCtD
Rosiglitazone—CYP2C8—Tazarotene—psoriasis	0.0351	0.0774	CbGbCtD
Rosiglitazone—CYP1A2—Clobetasol propionate—psoriasis	0.0334	0.0735	CbGbCtD
Rosiglitazone—SLCO1B1—Mycophenolate mofetil—psoriasis	0.0307	0.0677	CbGbCtD
Rosiglitazone—SLCO1B1—Cyclosporine—psoriasis	0.0233	0.0513	CbGbCtD
Rosiglitazone—CYP2A6—Prednisolone—psoriasis	0.0223	0.0492	CbGbCtD
Rosiglitazone—CYP1A2—Methoxsalen—psoriasis	0.0175	0.0386	CbGbCtD
Rosiglitazone—ALB—Mycophenolate mofetil—psoriasis	0.0168	0.0371	CbGbCtD
Rosiglitazone—CYP2D6—Hydroxyurea—psoriasis	0.0158	0.0348	CbGbCtD
Rosiglitazone—CYP2C8—Cholecalciferol—psoriasis	0.015	0.033	CbGbCtD
Rosiglitazone—ALB—Prednisone—psoriasis	0.0135	0.0296	CbGbCtD
Rosiglitazone—CYP2A6—Dexamethasone—psoriasis	0.0132	0.029	CbGbCtD
Rosiglitazone—CYP2C8—Mycophenolate mofetil—psoriasis	0.013	0.0286	CbGbCtD
Rosiglitazone—CYP2C19—Cholecalciferol—psoriasis	0.0126	0.0277	CbGbCtD
Rosiglitazone—SLCO1B1—Methotrexate—psoriasis	0.0123	0.0271	CbGbCtD
Rosiglitazone—CYP2C9—Cholecalciferol—psoriasis	0.0105	0.023	CbGbCtD
Rosiglitazone—CYP2C8—Hydrocortisone—psoriasis	0.0104	0.023	CbGbCtD
Rosiglitazone—CYP2C8—Cyclosporine—psoriasis	0.00986	0.0217	CbGbCtD
Rosiglitazone—CYP2D6—Cholecalciferol—psoriasis	0.00957	0.0211	CbGbCtD
Rosiglitazone—CYP2C19—Prednisone—psoriasis	0.00872	0.0192	CbGbCtD
Rosiglitazone—CYP2C19—Cyclosporine—psoriasis	0.00827	0.0182	CbGbCtD
Rosiglitazone—CYP2C9—Cyclosporine—psoriasis	0.00687	0.0151	CbGbCtD
Rosiglitazone—ALB—Methotrexate—psoriasis	0.00675	0.0149	CbGbCtD
Rosiglitazone—CYP2C8—Dexamethasone—psoriasis	0.00649	0.0143	CbGbCtD
Rosiglitazone—CYP2D6—Cyclosporine—psoriasis	0.00629	0.0138	CbGbCtD
Rosiglitazone—CYP2C19—Dexamethasone—psoriasis	0.00544	0.012	CbGbCtD
Rosiglitazone—CYP2C9—Dexamethasone—psoriasis	0.00453	0.00997	CbGbCtD
Rosiglitazone—CYP2D6—Dexamethasone—psoriasis	0.00414	0.00911	CbGbCtD
Rosiglitazone—Pioglitazone—PPARG—psoriasis	0.00224	1	CrCbGaD
Rosiglitazone—CYP2A6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000432	0.0137	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000416	0.0132	CbGpPWpGaD
Rosiglitazone—PPARG—RXR and RAR heterodimerization with other nuclear receptor—VDR—psoriasis	0.000376	0.0119	CbGpPWpGaD
Rosiglitazone—PTGS1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000375	0.0119	CbGpPWpGaD
Rosiglitazone—CYP2A6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000355	0.0113	CbGpPWpGaD
Rosiglitazone—PPARG—Transcription factor regulation in adipogenesis—LEP—psoriasis	0.000344	0.0109	CbGpPWpGaD
Rosiglitazone—PPARG—Differentiation of white and brown adipocyte   —LEP—psoriasis	0.00031	0.00985	CbGpPWpGaD
Rosiglitazone—PPARG—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000303	0.00962	CbGpPWpGaD
Rosiglitazone—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000299	0.00948	CbGpPWpGaD
Rosiglitazone—CYP2C8—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000295	0.00936	CbGpPWpGaD
Rosiglitazone—PPARG—Nuclear Receptors—VDR—psoriasis	0.000277	0.0088	CbGpPWpGaD
Rosiglitazone—PTGS1—Overview of nanoparticle effects—CRP—psoriasis	0.000277	0.00878	CbGpPWpGaD
Rosiglitazone—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKBIA—psoriasis	0.000274	0.00869	CbGpPWpGaD
Rosiglitazone—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000267	0.00846	CbGpPWpGaD
Rosiglitazone—PPARG—Transcriptional regulation of white adipocyte differentiation—CARM1—psoriasis	0.000264	0.00838	CbGpPWpGaD
Rosiglitazone—CYP2C19—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000263	0.00835	CbGpPWpGaD
Rosiglitazone—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000245	0.00778	CbGpPWpGaD
Rosiglitazone—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000243	0.00772	CbGpPWpGaD
Rosiglitazone—CYP2C8—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000242	0.00769	CbGpPWpGaD
Rosiglitazone—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000242	0.00768	CbGpPWpGaD
Rosiglitazone—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00024	0.00761	CbGpPWpGaD
Rosiglitazone—PPARG—Nuclear Receptor transcription pathway—VDR—psoriasis	0.000219	0.00696	CbGpPWpGaD
Rosiglitazone—CYP2C19—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000216	0.00686	CbGpPWpGaD
Rosiglitazone—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL4—psoriasis	0.000211	0.00669	CbGpPWpGaD
Rosiglitazone—ALB—HDL-mediated lipid transport—APOE—psoriasis	0.00021	0.00667	CbGpPWpGaD
Rosiglitazone—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000208	0.00659	CbGpPWpGaD
Rosiglitazone—CYP1A2—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000205	0.00651	CbGpPWpGaD
Rosiglitazone—PTGS1—Biological oxidations—CYP2S1—psoriasis	0.000199	0.00632	CbGpPWpGaD
Rosiglitazone—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000199	0.00631	CbGpPWpGaD
Rosiglitazone—PPARG—PPARA activates gene expression—CARM1—psoriasis	0.000199	0.0063	CbGpPWpGaD
Rosiglitazone—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000197	0.00626	CbGpPWpGaD
Rosiglitazone—PPARG—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CARM1—psoriasis	0.000194	0.00617	CbGpPWpGaD
Rosiglitazone—CYP2A6—Biological oxidations—CYP2S1—psoriasis	0.000188	0.00598	CbGpPWpGaD
Rosiglitazone—ACSL4—Metabolism—NDUFA5—psoriasis	0.000186	0.00591	CbGpPWpGaD
Rosiglitazone—ACSL4—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	0.000182	0.00576	CbGpPWpGaD
Rosiglitazone—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—psoriasis	0.000182	0.00576	CbGpPWpGaD
Rosiglitazone—PTGS1—Overview of nanoparticle effects—CXCL8—psoriasis	0.00018	0.00571	CbGpPWpGaD
Rosiglitazone—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKB1—psoriasis	0.000175	0.00555	CbGpPWpGaD
Rosiglitazone—ACSL4—Metabolism of lipids and lipoproteins—CARM1—psoriasis	0.000174	0.00551	CbGpPWpGaD
Rosiglitazone—CYP1A2—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000168	0.00535	CbGpPWpGaD
Rosiglitazone—Diarrhoea—Fluocinolone Acetonide—psoriasis	0.00016	0.00134	CcSEcCtD
Rosiglitazone—PPARG—Transcription factor regulation in adipogenesis—TNF—psoriasis	0.000159	0.00505	CbGpPWpGaD
Rosiglitazone—Cardiac disorder—Mycophenolate mofetil—psoriasis	0.000159	0.00133	CcSEcCtD
Rosiglitazone—Gastrointestinal disorder—Hydroxyurea—psoriasis	0.000159	0.00133	CcSEcCtD
Rosiglitazone—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—psoriasis	0.000159	0.00503	CbGpPWpGaD
Rosiglitazone—Fatigue—Hydroxyurea—psoriasis	0.000159	0.00133	CcSEcCtD
Rosiglitazone—ACSL4—Metabolism—CYP2S1—psoriasis	0.000158	0.00503	CbGpPWpGaD
Rosiglitazone—Constipation—Hydroxyurea—psoriasis	0.000157	0.00132	CcSEcCtD
Rosiglitazone—Nausea—Calcitriol—psoriasis	0.000156	0.00131	CcSEcCtD
Rosiglitazone—Hepatic failure—Methotrexate—psoriasis	0.000156	0.00131	CcSEcCtD
Rosiglitazone—Dizziness—Acitretin—psoriasis	0.000155	0.0013	CcSEcCtD
Rosiglitazone—Dizziness—Fluocinolone Acetonide—psoriasis	0.000154	0.0013	CcSEcCtD
Rosiglitazone—Oedema—Mycophenolic acid—psoriasis	0.000154	0.00129	CcSEcCtD
Rosiglitazone—Connective tissue disorder—Hydrocortisone—psoriasis	0.000153	0.00129	CcSEcCtD
Rosiglitazone—Infection—Mycophenolic acid—psoriasis	0.000153	0.00128	CcSEcCtD
Rosiglitazone—Malnutrition—Cyclosporine—psoriasis	0.000153	0.00128	CcSEcCtD
Rosiglitazone—Weight increased—Dexamethasone—psoriasis	0.000151	0.00127	CcSEcCtD
Rosiglitazone—Weight increased—Betamethasone—psoriasis	0.000151	0.00127	CcSEcCtD
Rosiglitazone—Nervous system disorder—Mycophenolic acid—psoriasis	0.000151	0.00127	CcSEcCtD
Rosiglitazone—Thrombocytopenia—Mycophenolic acid—psoriasis	0.000151	0.00127	CcSEcCtD
Rosiglitazone—Hyperglycaemia—Betamethasone—psoriasis	0.00015	0.00126	CcSEcCtD
Rosiglitazone—Hyperglycaemia—Dexamethasone—psoriasis	0.00015	0.00126	CcSEcCtD
Rosiglitazone—Malnutrition—Mycophenolate mofetil—psoriasis	0.000149	0.00125	CcSEcCtD
Rosiglitazone—Rash—Acitretin—psoriasis	0.000148	0.00124	CcSEcCtD
Rosiglitazone—Dermatitis—Acitretin—psoriasis	0.000148	0.00124	CcSEcCtD
Rosiglitazone—Rash—Fluocinolone Acetonide—psoriasis	0.000147	0.00124	CcSEcCtD
Rosiglitazone—Dermatitis—Fluocinolone Acetonide—psoriasis	0.000147	0.00123	CcSEcCtD
Rosiglitazone—Headache—Acitretin—psoriasis	0.000147	0.00123	CcSEcCtD
Rosiglitazone—Headache—Fluocinolone Acetonide—psoriasis	0.000146	0.00123	CcSEcCtD
Rosiglitazone—Acute coronary syndrome—Dexamethasone—psoriasis	0.000146	0.00123	CcSEcCtD
Rosiglitazone—Acute coronary syndrome—Betamethasone—psoriasis	0.000146	0.00123	CcSEcCtD
Rosiglitazone—Eye disorder—Hydrocortisone—psoriasis	0.000146	0.00122	CcSEcCtD
Rosiglitazone—Myocardial infarction—Betamethasone—psoriasis	0.000145	0.00122	CcSEcCtD
Rosiglitazone—Myocardial infarction—Dexamethasone—psoriasis	0.000145	0.00122	CcSEcCtD
Rosiglitazone—Back pain—Mycophenolate mofetil—psoriasis	0.000144	0.00121	CcSEcCtD
Rosiglitazone—Cerebrovascular accident—Methotrexate—psoriasis	0.000143	0.0012	CcSEcCtD
Rosiglitazone—Anaemia—Cyclosporine—psoriasis	0.000141	0.00118	CcSEcCtD
Rosiglitazone—Immune system disorder—Hydrocortisone—psoriasis	0.000141	0.00118	CcSEcCtD
Rosiglitazone—Musculoskeletal discomfort—Mycophenolic acid—psoriasis	0.00014	0.00118	CcSEcCtD
Rosiglitazone—Angioedema—Cyclosporine—psoriasis	0.00014	0.00117	CcSEcCtD
Rosiglitazone—PPARG—RXR and RAR heterodimerization with other nuclear receptor—TNF—psoriasis	0.000139	0.00442	CbGpPWpGaD
Rosiglitazone—Nausea—Acitretin—psoriasis	0.000139	0.00117	CcSEcCtD
Rosiglitazone—Nausea—Fluocinolone Acetonide—psoriasis	0.000139	0.00116	CcSEcCtD
Rosiglitazone—Anaemia—Mycophenolate mofetil—psoriasis	0.000138	0.00116	CcSEcCtD
Rosiglitazone—Leukopenia—Cyclosporine—psoriasis	0.000137	0.00115	CcSEcCtD
Rosiglitazone—Angioedema—Mycophenolate mofetil—psoriasis	0.000136	0.00114	CcSEcCtD
Rosiglitazone—Malnutrition—Hydrocortisone—psoriasis	0.000136	0.00114	CcSEcCtD
Rosiglitazone—PPARG—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	0.000134	0.00425	CbGpPWpGaD
Rosiglitazone—Leukopenia—Mycophenolate mofetil—psoriasis	0.000133	0.00112	CcSEcCtD
Rosiglitazone—Gastrointestinal disorder—Mycophenolic acid—psoriasis	0.000133	0.00112	CcSEcCtD
Rosiglitazone—Fatigue—Mycophenolic acid—psoriasis	0.000133	0.00111	CcSEcCtD
Rosiglitazone—Asthenia—Hydroxyurea—psoriasis	0.000132	0.00111	CcSEcCtD
Rosiglitazone—Weight increased—Prednisone—psoriasis	0.000132	0.00111	CcSEcCtD
Rosiglitazone—Hypertension—Cyclosporine—psoriasis	0.000132	0.00111	CcSEcCtD
Rosiglitazone—Constipation—Mycophenolic acid—psoriasis	0.000132	0.00111	CcSEcCtD
Rosiglitazone—Hyperglycaemia—Prednisone—psoriasis	0.000131	0.0011	CcSEcCtD
Rosiglitazone—Arthralgia—Cyclosporine—psoriasis	0.00013	0.00109	CcSEcCtD
Rosiglitazone—Myalgia—Cyclosporine—psoriasis	0.00013	0.00109	CcSEcCtD
Rosiglitazone—CYP2C8—Biological oxidations—CYP2S1—psoriasis	0.000129	0.00408	CbGpPWpGaD
Rosiglitazone—Hypertension—Mycophenolate mofetil—psoriasis	0.000129	0.00108	CcSEcCtD
Rosiglitazone—PPARG—Transcription factor regulation in adipogenesis—IL6—psoriasis	0.000128	0.00407	CbGpPWpGaD
Rosiglitazone—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—psoriasis	0.000127	0.00404	CbGpPWpGaD
Rosiglitazone—Acute coronary syndrome—Prednisone—psoriasis	0.000127	0.00107	CcSEcCtD
Rosiglitazone—Angioedema—Prednisolone—psoriasis	0.000127	0.00107	CcSEcCtD
Rosiglitazone—PPARG—Signaling events mediated by HDAC Class I—NFKBIA—psoriasis	0.000127	0.00403	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metapathway biotransformation—CYP2S1—psoriasis	0.000127	0.00403	CbGpPWpGaD
Rosiglitazone—Arthralgia—Mycophenolate mofetil—psoriasis	0.000127	0.00106	CcSEcCtD
Rosiglitazone—Myalgia—Mycophenolate mofetil—psoriasis	0.000127	0.00106	CcSEcCtD
Rosiglitazone—Myocardial infarction—Prednisone—psoriasis	0.000127	0.00106	CcSEcCtD
Rosiglitazone—PPARG—Transcriptional regulation of white adipocyte differentiation—LEP—psoriasis	0.000126	0.00401	CbGpPWpGaD
Rosiglitazone—Diarrhoea—Hydroxyurea—psoriasis	0.000126	0.00106	CcSEcCtD
Rosiglitazone—PTGS1—Overview of nanoparticle effects—TNF—psoriasis	0.000125	0.00398	CbGpPWpGaD
Rosiglitazone—Oedema—Cyclosporine—psoriasis	0.000125	0.00105	CcSEcCtD
Rosiglitazone—Anaphylactic shock—Cyclosporine—psoriasis	0.000125	0.00105	CcSEcCtD
Rosiglitazone—Eye disorder—Dexamethasone—psoriasis	0.000124	0.00104	CcSEcCtD
Rosiglitazone—Eye disorder—Betamethasone—psoriasis	0.000124	0.00104	CcSEcCtD
Rosiglitazone—Angioedema—Hydrocortisone—psoriasis	0.000124	0.00104	CcSEcCtD
Rosiglitazone—Infection—Cyclosporine—psoriasis	0.000124	0.00104	CcSEcCtD
Rosiglitazone—Back pain—Triamcinolone—psoriasis	0.000124	0.00104	CcSEcCtD
Rosiglitazone—Nervous system disorder—Cyclosporine—psoriasis	0.000122	0.00103	CcSEcCtD
Rosiglitazone—Thrombocytopenia—Cyclosporine—psoriasis	0.000122	0.00102	CcSEcCtD
Rosiglitazone—Dizziness—Hydroxyurea—psoriasis	0.000122	0.00102	CcSEcCtD
Rosiglitazone—Oedema—Mycophenolate mofetil—psoriasis	0.000122	0.00102	CcSEcCtD
Rosiglitazone—Anaphylactic shock—Mycophenolate mofetil—psoriasis	0.000122	0.00102	CcSEcCtD
Rosiglitazone—Infection—Mycophenolate mofetil—psoriasis	0.000121	0.00101	CcSEcCtD
Rosiglitazone—ALB—Lipoprotein metabolism—APOE—psoriasis	0.000121	0.00383	CbGpPWpGaD
Rosiglitazone—Hypertension—Prednisolone—psoriasis	0.00012	0.00101	CcSEcCtD
Rosiglitazone—Nervous system disorder—Mycophenolate mofetil—psoriasis	0.000119	0.001	CcSEcCtD
Rosiglitazone—Thrombocytopenia—Mycophenolate mofetil—psoriasis	0.000119	0.000999	CcSEcCtD
Rosiglitazone—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—psoriasis	0.000118	0.00376	CbGpPWpGaD
Rosiglitazone—Hypertension—Hydrocortisone—psoriasis	0.000117	0.000983	CcSEcCtD
Rosiglitazone—Angioedema—Triamcinolone—psoriasis	0.000117	0.00098	CcSEcCtD
Rosiglitazone—Rash—Hydroxyurea—psoriasis	0.000116	0.000973	CcSEcCtD
Rosiglitazone—Dermatitis—Hydroxyurea—psoriasis	0.000116	0.000972	CcSEcCtD
Rosiglitazone—Myalgia—Hydrocortisone—psoriasis	0.000116	0.000969	CcSEcCtD
Rosiglitazone—Headache—Hydroxyurea—psoriasis	0.000115	0.000967	CcSEcCtD
Rosiglitazone—CYP2C19—Biological oxidations—CYP2S1—psoriasis	0.000115	0.00364	CbGpPWpGaD
Rosiglitazone—Connective tissue disorder—Prednisone—psoriasis	0.000114	0.000956	CcSEcCtD
Rosiglitazone—Musculoskeletal discomfort—Cyclosporine—psoriasis	0.000114	0.000953	CcSEcCtD
Rosiglitazone—Oedema—Prednisolone—psoriasis	0.000113	0.000951	CcSEcCtD
Rosiglitazone—Anaphylactic shock—Prednisolone—psoriasis	0.000113	0.000951	CcSEcCtD
Rosiglitazone—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	0.000113	0.00359	CbGpPWpGaD
Rosiglitazone—Upper respiratory tract infection—Methotrexate—psoriasis	0.000113	0.000944	CcSEcCtD
Rosiglitazone—PPARG—Adipogenesis—SOCS1—psoriasis	0.000112	0.00357	CbGpPWpGaD
Rosiglitazone—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000112	0.00354	CbGpPWpGaD
Rosiglitazone—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	0.000111	0.00353	CbGpPWpGaD
Rosiglitazone—Musculoskeletal discomfort—Mycophenolate mofetil—psoriasis	0.000111	0.000929	CcSEcCtD
Rosiglitazone—Anaphylactic shock—Hydrocortisone—psoriasis	0.000111	0.000929	CcSEcCtD
Rosiglitazone—Oedema—Hydrocortisone—psoriasis	0.000111	0.000929	CcSEcCtD
Rosiglitazone—Asthenia—Mycophenolic acid—psoriasis	0.000111	0.000927	CcSEcCtD
Rosiglitazone—Hypertension—Triamcinolone—psoriasis	0.00011	0.000926	CcSEcCtD
Rosiglitazone—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—psoriasis	0.00011	0.0035	CbGpPWpGaD
Rosiglitazone—Infection—Hydrocortisone—psoriasis	0.00011	0.000923	CcSEcCtD
Rosiglitazone—Nausea—Hydroxyurea—psoriasis	0.000109	0.000917	CcSEcCtD
Rosiglitazone—Pruritus—Mycophenolic acid—psoriasis	0.000109	0.000914	CcSEcCtD
Rosiglitazone—Myalgia—Triamcinolone—psoriasis	0.000109	0.000913	CcSEcCtD
Rosiglitazone—Nervous system disorder—Hydrocortisone—psoriasis	0.000109	0.000911	CcSEcCtD
Rosiglitazone—Eye disorder—Prednisone—psoriasis	0.000108	0.000909	CcSEcCtD
Rosiglitazone—Gastrointestinal disorder—Cyclosporine—psoriasis	0.000108	0.000903	CcSEcCtD
Rosiglitazone—Fatigue—Cyclosporine—psoriasis	0.000107	0.000901	CcSEcCtD
Rosiglitazone—Stevens-Johnson syndrome—Methotrexate—psoriasis	0.000107	0.000898	CcSEcCtD
Rosiglitazone—Constipation—Cyclosporine—psoriasis	0.000107	0.000894	CcSEcCtD
Rosiglitazone—Angioedema—Dexamethasone—psoriasis	0.000106	0.000889	CcSEcCtD
Rosiglitazone—Angioedema—Betamethasone—psoriasis	0.000106	0.000889	CcSEcCtD
Rosiglitazone—CYP2D6—Biological oxidations—CYP2S1—psoriasis	0.000106	0.00335	CbGpPWpGaD
Rosiglitazone—Diarrhoea—Mycophenolic acid—psoriasis	0.000105	0.000884	CcSEcCtD
Rosiglitazone—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000105	0.000881	CcSEcCtD
Rosiglitazone—CYP2A6—NRF2 pathway—TGFA—psoriasis	0.000105	0.00333	CbGpPWpGaD
Rosiglitazone—Immune system disorder—Prednisone—psoriasis	0.000105	0.000879	CcSEcCtD
Rosiglitazone—CYP2C9—Biological oxidations—CYP2S1—psoriasis	0.000105	0.00332	CbGpPWpGaD
Rosiglitazone—Oedema—Triamcinolone—psoriasis	0.000104	0.000875	CcSEcCtD
Rosiglitazone—Anaphylactic shock—Triamcinolone—psoriasis	0.000104	0.000875	CcSEcCtD
Rosiglitazone—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	0.000104	0.00331	CbGpPWpGaD
Rosiglitazone—Constipation—Mycophenolate mofetil—psoriasis	0.000104	0.000872	CcSEcCtD
Rosiglitazone—Infection—Triamcinolone—psoriasis	0.000104	0.000869	CcSEcCtD
Rosiglitazone—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	0.000103	0.00328	CbGpPWpGaD
Rosiglitazone—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	0.000102	0.00325	CbGpPWpGaD
Rosiglitazone—PTGS1—Selenium Micronutrient Network—CAT—psoriasis	0.000102	0.00325	CbGpPWpGaD
Rosiglitazone—Hepatobiliary disease—Methotrexate—psoriasis	0.000102	0.000857	CcSEcCtD
Rosiglitazone—Dizziness—Mycophenolic acid—psoriasis	0.000102	0.000855	CcSEcCtD
Rosiglitazone—CYP1A2—Estrogen Receptor Pathway—JUN—psoriasis	0.000102	0.00323	CbGpPWpGaD
Rosiglitazone—PTGS1—Overview of nanoparticle effects—IL6—psoriasis	0.000101	0.00321	CbGpPWpGaD
Rosiglitazone—Malnutrition—Prednisone—psoriasis	0.000101	0.000847	CcSEcCtD
Rosiglitazone—Musculoskeletal discomfort—Hydrocortisone—psoriasis	0.000101	0.000847	CcSEcCtD
Rosiglitazone—Hypertension—Betamethasone—psoriasis	0.0001	0.00084	CcSEcCtD
Rosiglitazone—Hypertension—Dexamethasone—psoriasis	0.0001	0.00084	CcSEcCtD
Rosiglitazone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	9.97e-05	0.00316	CbGpPWpGaD
Rosiglitazone—Urticaria—Cyclosporine—psoriasis	9.9e-05	0.000831	CcSEcCtD
Rosiglitazone—Myalgia—Dexamethasone—psoriasis	9.87e-05	0.000828	CcSEcCtD
Rosiglitazone—Myalgia—Betamethasone—psoriasis	9.87e-05	0.000828	CcSEcCtD
Rosiglitazone—ALB—Hemostasis—SERPINB8—psoriasis	9.85e-05	0.00313	CbGpPWpGaD
Rosiglitazone—Rash—Mycophenolic acid—psoriasis	9.71e-05	0.000815	CcSEcCtD
Rosiglitazone—PPARG—Gene Expression—TARS—psoriasis	9.7e-05	0.00308	CbGpPWpGaD
Rosiglitazone—Dermatitis—Mycophenolic acid—psoriasis	9.7e-05	0.000814	CcSEcCtD
Rosiglitazone—Hepatitis—Methotrexate—psoriasis	9.69e-05	0.000813	CcSEcCtD
Rosiglitazone—Urticaria—Mycophenolate mofetil—psoriasis	9.66e-05	0.00081	CcSEcCtD
Rosiglitazone—Headache—Mycophenolic acid—psoriasis	9.65e-05	0.00081	CcSEcCtD
Rosiglitazone—Gastrointestinal disorder—Hydrocortisone—psoriasis	9.56e-05	0.000802	CcSEcCtD
Rosiglitazone—Fatigue—Hydrocortisone—psoriasis	9.55e-05	0.000801	CcSEcCtD
Rosiglitazone—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	9.54e-05	0.00303	CbGpPWpGaD
Rosiglitazone—Musculoskeletal discomfort—Triamcinolone—psoriasis	9.5e-05	0.000797	CcSEcCtD
Rosiglitazone—Oedema—Dexamethasone—psoriasis	9.46e-05	0.000794	CcSEcCtD
Rosiglitazone—Anaphylactic shock—Betamethasone—psoriasis	9.46e-05	0.000794	CcSEcCtD
Rosiglitazone—Oedema—Betamethasone—psoriasis	9.46e-05	0.000794	CcSEcCtD
Rosiglitazone—Anaphylactic shock—Dexamethasone—psoriasis	9.46e-05	0.000794	CcSEcCtD
Rosiglitazone—ALB—Binding and Uptake of Ligands by Scavenger Receptors—APOE—psoriasis	9.4e-05	0.00298	CbGpPWpGaD
Rosiglitazone—Infection—Betamethasone—psoriasis	9.4e-05	0.000789	CcSEcCtD
Rosiglitazone—Infection—Dexamethasone—psoriasis	9.4e-05	0.000789	CcSEcCtD
Rosiglitazone—Anaemia—Prednisone—psoriasis	9.33e-05	0.000783	CcSEcCtD
Rosiglitazone—Nervous system disorder—Dexamethasone—psoriasis	9.28e-05	0.000779	CcSEcCtD
Rosiglitazone—Nervous system disorder—Betamethasone—psoriasis	9.28e-05	0.000779	CcSEcCtD
Rosiglitazone—Thrombocytopenia—Dexamethasone—psoriasis	9.26e-05	0.000777	CcSEcCtD
Rosiglitazone—Thrombocytopenia—Betamethasone—psoriasis	9.26e-05	0.000777	CcSEcCtD
Rosiglitazone—Angioedema—Prednisone—psoriasis	9.22e-05	0.000774	CcSEcCtD
Rosiglitazone—Erythema multiforme—Methotrexate—psoriasis	9.16e-05	0.000769	CcSEcCtD
Rosiglitazone—Nausea—Mycophenolic acid—psoriasis	9.15e-05	0.000768	CcSEcCtD
Rosiglitazone—Eye disorder—Methotrexate—psoriasis	9.06e-05	0.00076	CcSEcCtD
Rosiglitazone—Urticaria—Prednisolone—psoriasis	9.01e-05	0.000756	CcSEcCtD
Rosiglitazone—Cardiac disorder—Methotrexate—psoriasis	9e-05	0.000755	CcSEcCtD
Rosiglitazone—Fatigue—Triamcinolone—psoriasis	8.99e-05	0.000754	CcSEcCtD
Rosiglitazone—CYP1A2—Biological oxidations—CYP2S1—psoriasis	8.95e-05	0.00284	CbGpPWpGaD
Rosiglitazone—Asthenia—Cyclosporine—psoriasis	8.94e-05	0.00075	CcSEcCtD
Rosiglitazone—CYP1A2—Metapathway biotransformation—CYP2S1—psoriasis	8.82e-05	0.0028	CbGpPWpGaD
Rosiglitazone—PPARG—Regulation of retinoblastoma protein—JUN—psoriasis	8.82e-05	0.0028	CbGpPWpGaD
Rosiglitazone—Pruritus—Cyclosporine—psoriasis	8.82e-05	0.00074	CcSEcCtD
Rosiglitazone—CYP1A2—Estrogen Receptor Pathway—STAT3—psoriasis	8.81e-05	0.0028	CbGpPWpGaD
Rosiglitazone—Urticaria—Hydrocortisone—psoriasis	8.8e-05	0.000738	CcSEcCtD
Rosiglitazone—Immune system disorder—Methotrexate—psoriasis	8.75e-05	0.000735	CcSEcCtD
Rosiglitazone—Asthenia—Mycophenolate mofetil—psoriasis	8.72e-05	0.000732	CcSEcCtD
Rosiglitazone—Hypertension—Prednisone—psoriasis	8.72e-05	0.000731	CcSEcCtD
Rosiglitazone—CYP1A2—Melatonin metabolism and effects—APOE—psoriasis	8.67e-05	0.00275	CbGpPWpGaD
Rosiglitazone—Musculoskeletal discomfort—Dexamethasone—psoriasis	8.62e-05	0.000723	CcSEcCtD
Rosiglitazone—Musculoskeletal discomfort—Betamethasone—psoriasis	8.62e-05	0.000723	CcSEcCtD
Rosiglitazone—Pruritus—Mycophenolate mofetil—psoriasis	8.6e-05	0.000722	CcSEcCtD
Rosiglitazone—Arthralgia—Prednisone—psoriasis	8.59e-05	0.000721	CcSEcCtD
Rosiglitazone—Myalgia—Prednisone—psoriasis	8.59e-05	0.000721	CcSEcCtD
Rosiglitazone—Diarrhoea—Cyclosporine—psoriasis	8.53e-05	0.000715	CcSEcCtD
Rosiglitazone—Malnutrition—Methotrexate—psoriasis	8.44e-05	0.000708	CcSEcCtD
Rosiglitazone—Diarrhoea—Mycophenolate mofetil—psoriasis	8.32e-05	0.000698	CcSEcCtD
Rosiglitazone—ACSL4—Metabolism of lipids and lipoproteins—APOE—psoriasis	8.3e-05	0.00263	CbGpPWpGaD
Rosiglitazone—PPARG—Adipogenesis—LEP—psoriasis	8.3e-05	0.00263	CbGpPWpGaD
Rosiglitazone—Urticaria—Triamcinolone—psoriasis	8.28e-05	0.000695	CcSEcCtD
Rosiglitazone—ALB—Folate Metabolism—CAT—psoriasis	8.27e-05	0.00262	CbGpPWpGaD
Rosiglitazone—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—psoriasis	8.25e-05	0.00262	CbGpPWpGaD
Rosiglitazone—Dizziness—Cyclosporine—psoriasis	8.24e-05	0.000691	CcSEcCtD
Rosiglitazone—Oedema—Prednisone—psoriasis	8.24e-05	0.000691	CcSEcCtD
Rosiglitazone—Anaphylactic shock—Prednisone—psoriasis	8.24e-05	0.000691	CcSEcCtD
Rosiglitazone—SLCO1B1—SLC-mediated transmembrane transport—CP—psoriasis	8.23e-05	0.00261	CbGpPWpGaD
Rosiglitazone—Infection—Prednisone—psoriasis	8.19e-05	0.000687	CcSEcCtD
Rosiglitazone—Gastrointestinal disorder—Dexamethasone—psoriasis	8.17e-05	0.000685	CcSEcCtD
Rosiglitazone—Gastrointestinal disorder—Betamethasone—psoriasis	8.17e-05	0.000685	CcSEcCtD
Rosiglitazone—Back pain—Methotrexate—psoriasis	8.16e-05	0.000685	CcSEcCtD
Rosiglitazone—Fatigue—Betamethasone—psoriasis	8.16e-05	0.000684	CcSEcCtD
Rosiglitazone—Fatigue—Dexamethasone—psoriasis	8.16e-05	0.000684	CcSEcCtD
Rosiglitazone—PTGS1—Selenium Micronutrient Network—CRP—psoriasis	8.12e-05	0.00258	CbGpPWpGaD
Rosiglitazone—PPARG—Signaling events mediated by HDAC Class I—NFKB1—psoriasis	8.1e-05	0.00257	CbGpPWpGaD
Rosiglitazone—Nervous system disorder—Prednisone—psoriasis	8.08e-05	0.000678	CcSEcCtD
Rosiglitazone—ALB—Vitamin B12 Metabolism—CRP—psoriasis	8.07e-05	0.00256	CbGpPWpGaD
Rosiglitazone—Dizziness—Mycophenolate mofetil—psoriasis	8.04e-05	0.000674	CcSEcCtD
Rosiglitazone—ALB—Lipid and lipoprotein metabolism—APOE—psoriasis	8.02e-05	0.00255	CbGpPWpGaD
Rosiglitazone—Asthenia—Hydrocortisone—psoriasis	7.95e-05	0.000667	CcSEcCtD
Rosiglitazone—ALB—Vitamin B12 Metabolism—APOE—psoriasis	7.89e-05	0.00251	CbGpPWpGaD
Rosiglitazone—Rash—Cyclosporine—psoriasis	7.86e-05	0.000659	CcSEcCtD
Rosiglitazone—Dermatitis—Cyclosporine—psoriasis	7.85e-05	0.000659	CcSEcCtD
Rosiglitazone—Pruritus—Hydrocortisone—psoriasis	7.83e-05	0.000657	CcSEcCtD
Rosiglitazone—Headache—Cyclosporine—psoriasis	7.81e-05	0.000655	CcSEcCtD
Rosiglitazone—Anaemia—Methotrexate—psoriasis	7.8e-05	0.000654	CcSEcCtD
Rosiglitazone—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	7.79e-05	0.00247	CbGpPWpGaD
Rosiglitazone—ACSL4—Metabolism—CARM1—psoriasis	7.74e-05	0.00246	CbGpPWpGaD
Rosiglitazone—CYP1A2—Tryptophan metabolism—CAT—psoriasis	7.72e-05	0.00245	CbGpPWpGaD
Rosiglitazone—Rash—Mycophenolate mofetil—psoriasis	7.66e-05	0.000643	CcSEcCtD
Rosiglitazone—Dermatitis—Mycophenolate mofetil—psoriasis	7.66e-05	0.000642	CcSEcCtD
Rosiglitazone—Headache—Mycophenolate mofetil—psoriasis	7.61e-05	0.000639	CcSEcCtD
Rosiglitazone—ALB—Folate Metabolism—IL4—psoriasis	7.59e-05	0.00241	CbGpPWpGaD
Rosiglitazone—Diarrhoea—Hydrocortisone—psoriasis	7.58e-05	0.000636	CcSEcCtD
Rosiglitazone—Leukopenia—Methotrexate—psoriasis	7.55e-05	0.000634	CcSEcCtD
Rosiglitazone—Urticaria—Dexamethasone—psoriasis	7.52e-05	0.000631	CcSEcCtD
Rosiglitazone—Urticaria—Betamethasone—psoriasis	7.52e-05	0.000631	CcSEcCtD
Rosiglitazone—Musculoskeletal discomfort—Prednisone—psoriasis	7.51e-05	0.00063	CcSEcCtD
Rosiglitazone—PPARG—Transcriptional regulation of white adipocyte differentiation—NFKB1—psoriasis	7.51e-05	0.00238	CbGpPWpGaD
Rosiglitazone—Dizziness—Prednisolone—psoriasis	7.5e-05	0.000629	CcSEcCtD
Rosiglitazone—Asthenia—Triamcinolone—psoriasis	7.48e-05	0.000628	CcSEcCtD
Rosiglitazone—PTGS1—Selenium Micronutrient Network—ICAM1—psoriasis	7.46e-05	0.00237	CbGpPWpGaD
Rosiglitazone—ALB—Vitamin B12 Metabolism—ICAM1—psoriasis	7.42e-05	0.00235	CbGpPWpGaD
Rosiglitazone—Nausea—Cyclosporine—psoriasis	7.4e-05	0.000621	CcSEcCtD
Rosiglitazone—Pruritus—Triamcinolone—psoriasis	7.38e-05	0.000619	CcSEcCtD
Rosiglitazone—Dizziness—Hydrocortisone—psoriasis	7.32e-05	0.000614	CcSEcCtD
Rosiglitazone—PPARG—Signaling events mediated by HDAC Class I—STAT3—psoriasis	7.28e-05	0.00231	CbGpPWpGaD
Rosiglitazone—ACSL4—Metabolism of lipids and lipoproteins—PPARG—psoriasis	7.23e-05	0.0023	CbGpPWpGaD
Rosiglitazone—Nausea—Mycophenolate mofetil—psoriasis	7.22e-05	0.000606	CcSEcCtD
Rosiglitazone—Arthralgia—Methotrexate—psoriasis	7.18e-05	0.000603	CcSEcCtD
Rosiglitazone—Myalgia—Methotrexate—psoriasis	7.18e-05	0.000603	CcSEcCtD
Rosiglitazone—Rash—Prednisolone—psoriasis	7.15e-05	0.0006	CcSEcCtD
Rosiglitazone—Dermatitis—Prednisolone—psoriasis	7.14e-05	0.000599	CcSEcCtD
Rosiglitazone—Fatigue—Prednisone—psoriasis	7.1e-05	0.000596	CcSEcCtD
Rosiglitazone—Headache—Prednisolone—psoriasis	7.1e-05	0.000596	CcSEcCtD
Rosiglitazone—Constipation—Prednisone—psoriasis	7.05e-05	0.000591	CcSEcCtD
Rosiglitazone—Rash—Hydrocortisone—psoriasis	6.98e-05	0.000586	CcSEcCtD
Rosiglitazone—Dermatitis—Hydrocortisone—psoriasis	6.98e-05	0.000585	CcSEcCtD
Rosiglitazone—Headache—Hydrocortisone—psoriasis	6.94e-05	0.000582	CcSEcCtD
Rosiglitazone—Dizziness—Triamcinolone—psoriasis	6.9e-05	0.000579	CcSEcCtD
Rosiglitazone—Anaphylactic shock—Methotrexate—psoriasis	6.89e-05	0.000578	CcSEcCtD
Rosiglitazone—Infection—Methotrexate—psoriasis	6.84e-05	0.000574	CcSEcCtD
Rosiglitazone—Asthenia—Dexamethasone—psoriasis	6.79e-05	0.00057	CcSEcCtD
Rosiglitazone—Asthenia—Betamethasone—psoriasis	6.79e-05	0.00057	CcSEcCtD
Rosiglitazone—Nervous system disorder—Methotrexate—psoriasis	6.75e-05	0.000567	CcSEcCtD
Rosiglitazone—Thrombocytopenia—Methotrexate—psoriasis	6.74e-05	0.000566	CcSEcCtD
Rosiglitazone—Nausea—Prednisolone—psoriasis	6.73e-05	0.000565	CcSEcCtD
Rosiglitazone—CYP2A6—Fluoropyrimidine Activity—TP53—psoriasis	6.72e-05	0.00213	CbGpPWpGaD
Rosiglitazone—Pruritus—Betamethasone—psoriasis	6.69e-05	0.000562	CcSEcCtD
Rosiglitazone—Pruritus—Dexamethasone—psoriasis	6.69e-05	0.000562	CcSEcCtD
Rosiglitazone—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	6.65e-05	0.00211	CbGpPWpGaD
Rosiglitazone—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	6.62e-05	0.0021	CbGpPWpGaD
Rosiglitazone—Nausea—Hydrocortisone—psoriasis	6.58e-05	0.000552	CcSEcCtD
Rosiglitazone—Rash—Triamcinolone—psoriasis	6.57e-05	0.000552	CcSEcCtD
Rosiglitazone—Dermatitis—Triamcinolone—psoriasis	6.57e-05	0.000551	CcSEcCtD
Rosiglitazone—ALB—Selenium Micronutrient Network—CAT—psoriasis	6.57e-05	0.00208	CbGpPWpGaD
Rosiglitazone—ALB—Folate Metabolism—CRP—psoriasis	6.56e-05	0.00208	CbGpPWpGaD
Rosiglitazone—Urticaria—Prednisone—psoriasis	6.55e-05	0.000549	CcSEcCtD
Rosiglitazone—Headache—Triamcinolone—psoriasis	6.53e-05	0.000548	CcSEcCtD
Rosiglitazone—Diarrhoea—Dexamethasone—psoriasis	6.47e-05	0.000543	CcSEcCtD
Rosiglitazone—Diarrhoea—Betamethasone—psoriasis	6.47e-05	0.000543	CcSEcCtD
Rosiglitazone—PPARG—Generic Transcription Pathway—CARM1—psoriasis	6.34e-05	0.00201	CbGpPWpGaD
Rosiglitazone—PPARG—Signaling events mediated by HDAC Class I—TNF—psoriasis	6.3e-05	0.002	CbGpPWpGaD
Rosiglitazone—Musculoskeletal discomfort—Methotrexate—psoriasis	6.27e-05	0.000526	CcSEcCtD
Rosiglitazone—Dizziness—Dexamethasone—psoriasis	6.26e-05	0.000525	CcSEcCtD
Rosiglitazone—Dizziness—Betamethasone—psoriasis	6.26e-05	0.000525	CcSEcCtD
Rosiglitazone—Nausea—Triamcinolone—psoriasis	6.19e-05	0.00052	CcSEcCtD
Rosiglitazone—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	6.09e-05	0.00193	CbGpPWpGaD
Rosiglitazone—ALB—Folate Metabolism—ICAM1—psoriasis	6.03e-05	0.00191	CbGpPWpGaD
Rosiglitazone—PPARG—Developmental Biology—CARM1—psoriasis	5.97e-05	0.00189	CbGpPWpGaD
Rosiglitazone—Rash—Dexamethasone—psoriasis	5.97e-05	0.000501	CcSEcCtD
Rosiglitazone—Rash—Betamethasone—psoriasis	5.97e-05	0.000501	CcSEcCtD
Rosiglitazone—Dermatitis—Betamethasone—psoriasis	5.96e-05	0.0005	CcSEcCtD
Rosiglitazone—Dermatitis—Dexamethasone—psoriasis	5.96e-05	0.0005	CcSEcCtD
Rosiglitazone—Gastrointestinal disorder—Methotrexate—psoriasis	5.94e-05	0.000499	CcSEcCtD
Rosiglitazone—Fatigue—Methotrexate—psoriasis	5.94e-05	0.000498	CcSEcCtD
Rosiglitazone—Headache—Betamethasone—psoriasis	5.93e-05	0.000497	CcSEcCtD
Rosiglitazone—Headache—Dexamethasone—psoriasis	5.93e-05	0.000497	CcSEcCtD
Rosiglitazone—Asthenia—Prednisone—psoriasis	5.91e-05	0.000496	CcSEcCtD
Rosiglitazone—PPARG—Circadian rythm related genes—LEP—psoriasis	5.86e-05	0.00186	CbGpPWpGaD
Rosiglitazone—PPARG—Transcriptional regulation of white adipocyte differentiation—TNF—psoriasis	5.84e-05	0.00185	CbGpPWpGaD
Rosiglitazone—Pruritus—Prednisone—psoriasis	5.83e-05	0.000489	CcSEcCtD
Rosiglitazone—PPARG—Metabolism—NDUFA5—psoriasis	5.72e-05	0.00181	CbGpPWpGaD
Rosiglitazone—PTGS1—Selenium Micronutrient Network—IFNG—psoriasis	5.68e-05	0.0018	CbGpPWpGaD
Rosiglitazone—ALB—Vitamin B12 Metabolism—IFNG—psoriasis	5.64e-05	0.00179	CbGpPWpGaD
Rosiglitazone—Diarrhoea—Prednisone—psoriasis	5.64e-05	0.000473	CcSEcCtD
Rosiglitazone—Nausea—Betamethasone—psoriasis	5.62e-05	0.000472	CcSEcCtD
Rosiglitazone—Nausea—Dexamethasone—psoriasis	5.62e-05	0.000472	CcSEcCtD
Rosiglitazone—Urticaria—Methotrexate—psoriasis	5.47e-05	0.000459	CcSEcCtD
Rosiglitazone—PPARG—Circadian rythm related genes—NOS2—psoriasis	5.46e-05	0.00173	CbGpPWpGaD
Rosiglitazone—Dizziness—Prednisone—psoriasis	5.45e-05	0.000457	CcSEcCtD
Rosiglitazone—PPARG—Metabolism of lipids and lipoproteins—CARM1—psoriasis	5.33e-05	0.00169	CbGpPWpGaD
Rosiglitazone—ALB—Selenium Micronutrient Network—CRP—psoriasis	5.21e-05	0.00165	CbGpPWpGaD
Rosiglitazone—Rash—Prednisone—psoriasis	5.19e-05	0.000436	CcSEcCtD
Rosiglitazone—Dermatitis—Prednisone—psoriasis	5.19e-05	0.000436	CcSEcCtD
Rosiglitazone—Headache—Prednisone—psoriasis	5.16e-05	0.000433	CcSEcCtD
Rosiglitazone—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	5.16e-05	0.00164	CbGpPWpGaD
Rosiglitazone—Asthenia—Methotrexate—psoriasis	4.94e-05	0.000415	CcSEcCtD
Rosiglitazone—Nausea—Prednisone—psoriasis	4.89e-05	0.000411	CcSEcCtD
Rosiglitazone—Pruritus—Methotrexate—psoriasis	4.87e-05	0.000409	CcSEcCtD
Rosiglitazone—PPARG—Metabolism—CYP2S1—psoriasis	4.86e-05	0.00154	CbGpPWpGaD
Rosiglitazone—ALB—Selenium Micronutrient Network—ICAM1—psoriasis	4.79e-05	0.00152	CbGpPWpGaD
Rosiglitazone—ACSL4—Metabolism—CAT—psoriasis	4.76e-05	0.00151	CbGpPWpGaD
Rosiglitazone—PTGS1—Selenium Micronutrient Network—NFKB1—psoriasis	4.72e-05	0.0015	CbGpPWpGaD
Rosiglitazone—Diarrhoea—Methotrexate—psoriasis	4.71e-05	0.000395	CcSEcCtD
Rosiglitazone—ALB—SLC-mediated transmembrane transport—CP—psoriasis	4.7e-05	0.00149	CbGpPWpGaD
Rosiglitazone—ALB—Vitamin B12 Metabolism—NFKB1—psoriasis	4.69e-05	0.00149	CbGpPWpGaD
Rosiglitazone—ALB—Folate Metabolism—IFNG—psoriasis	4.59e-05	0.00146	CbGpPWpGaD
Rosiglitazone—Dizziness—Methotrexate—psoriasis	4.55e-05	0.000382	CcSEcCtD
Rosiglitazone—SLCO1B1—Metabolism—NDUFA5—psoriasis	4.5e-05	0.00143	CbGpPWpGaD
Rosiglitazone—PPARG—Adipogenesis—STAT3—psoriasis	4.44e-05	0.00141	CbGpPWpGaD
Rosiglitazone—Rash—Methotrexate—psoriasis	4.34e-05	0.000364	CcSEcCtD
Rosiglitazone—Dermatitis—Methotrexate—psoriasis	4.34e-05	0.000364	CcSEcCtD
Rosiglitazone—Headache—Methotrexate—psoriasis	4.31e-05	0.000362	CcSEcCtD
Rosiglitazone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	4.29e-05	0.00136	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.2e-05	0.00133	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Transmembrane transport of small molecules—CP—psoriasis	4.18e-05	0.00133	CbGpPWpGaD
Rosiglitazone—Nausea—Methotrexate—psoriasis	4.09e-05	0.000343	CcSEcCtD
Rosiglitazone—PTGS1—Metabolism—NDUFA5—psoriasis	4.01e-05	0.00127	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Transmembrane transport of small molecules—CARM1—psoriasis	3.99e-05	0.00127	CbGpPWpGaD
Rosiglitazone—PPARG—Adipogenesis—TNF—psoriasis	3.84e-05	0.00122	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—CYP2S1—psoriasis	3.83e-05	0.00122	CbGpPWpGaD
Rosiglitazone—ALB—Folate Metabolism—NFKB1—psoriasis	3.82e-05	0.00121	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—NDUFA5—psoriasis	3.79e-05	0.0012	CbGpPWpGaD
Rosiglitazone—PPARG—Generic Transcription Pathway—VDR—psoriasis	3.79e-05	0.0012	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.73e-05	0.00119	CbGpPWpGaD
Rosiglitazone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	3.71e-05	0.00118	CbGpPWpGaD
Rosiglitazone—ACSL4—Metabolism—APOE—psoriasis	3.7e-05	0.00117	CbGpPWpGaD
Rosiglitazone—PTGS1—Selenium Micronutrient Network—TNF—psoriasis	3.68e-05	0.00117	CbGpPWpGaD
Rosiglitazone—ALB—Vitamin B12 Metabolism—TNF—psoriasis	3.65e-05	0.00116	CbGpPWpGaD
Rosiglitazone—ALB—Selenium Micronutrient Network—IFNG—psoriasis	3.65e-05	0.00116	CbGpPWpGaD
Rosiglitazone—PPARG—Circadian rythm related genes—JUN—psoriasis	3.62e-05	0.00115	CbGpPWpGaD
Rosiglitazone—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	3.57e-05	0.00113	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—CYP2S1—psoriasis	3.41e-05	0.00108	CbGpPWpGaD
Rosiglitazone—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	3.24e-05	0.00103	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—CYP2S1—psoriasis	3.22e-05	0.00102	CbGpPWpGaD
Rosiglitazone—ACSL4—Metabolism—PPARG—psoriasis	3.22e-05	0.00102	CbGpPWpGaD
Rosiglitazone—PPARG—Adipogenesis—IL6—psoriasis	3.1e-05	0.000983	CbGpPWpGaD
Rosiglitazone—PPARG—Gene Expression—CARM1—psoriasis	3.05e-05	0.000969	CbGpPWpGaD
Rosiglitazone—ALB—Selenium Micronutrient Network—NFKB1—psoriasis	3.03e-05	0.000963	CbGpPWpGaD
Rosiglitazone—ALB—Platelet degranulation—VEGFA—psoriasis	2.97e-05	0.000943	CbGpPWpGaD
Rosiglitazone—ALB—Folate Metabolism—TNF—psoriasis	2.97e-05	0.000943	CbGpPWpGaD
Rosiglitazone—PTGS1—Selenium Micronutrient Network—IL6—psoriasis	2.97e-05	0.000941	CbGpPWpGaD
Rosiglitazone—ALB—Vitamin B12 Metabolism—IL6—psoriasis	2.95e-05	0.000935	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—ITGAL—psoriasis	2.86e-05	0.000908	CbGpPWpGaD
Rosiglitazone—PPARG—Developmental Biology—LEP—psoriasis	2.85e-05	0.000905	CbGpPWpGaD
Rosiglitazone—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—psoriasis	2.83e-05	0.000899	CbGpPWpGaD
Rosiglitazone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	2.77e-05	0.00088	CbGpPWpGaD
Rosiglitazone—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	2.77e-05	0.00088	CbGpPWpGaD
Rosiglitazone—ALB—Folate Metabolism—TP53—psoriasis	2.62e-05	0.000831	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—NDUFA5—psoriasis	2.59e-05	0.000821	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—NDUFA5—psoriasis	2.57e-05	0.000816	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.55e-05	0.000809	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.41e-05	0.000766	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.4e-05	0.000761	CbGpPWpGaD
Rosiglitazone—ALB—Folate Metabolism—IL6—psoriasis	2.4e-05	0.000761	CbGpPWpGaD
Rosiglitazone—ALB—Transmembrane transport of small molecules—CP—psoriasis	2.39e-05	0.000759	CbGpPWpGaD
Rosiglitazone—PPARG—Circadian rythm related genes—TP53—psoriasis	2.39e-05	0.000758	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism—CARM1—psoriasis	2.37e-05	0.000754	CbGpPWpGaD
Rosiglitazone—ALB—Selenium Micronutrient Network—TNF—psoriasis	2.36e-05	0.000749	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—NDUFA5—psoriasis	2.31e-05	0.000733	CbGpPWpGaD
Rosiglitazone—ALB—Transmembrane transport of small molecules—CARM1—psoriasis	2.28e-05	0.000724	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—CYP2S1—psoriasis	2.2e-05	0.000698	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—CYP2S1—psoriasis	2.19e-05	0.000694	CbGpPWpGaD
Rosiglitazone—PPARG—Circadian rythm related genes—IL6—psoriasis	2.19e-05	0.000694	CbGpPWpGaD
Rosiglitazone—PPARG—Developmental Biology—TYK2—psoriasis	2.18e-05	0.000691	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.15e-05	0.000683	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—NDUFA5—psoriasis	2.12e-05	0.000674	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—NDUFA5—psoriasis	2.11e-05	0.000668	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.01e-05	0.000637	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—CYP2S1—psoriasis	1.96e-05	0.000623	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.96e-05	0.000623	CbGpPWpGaD
Rosiglitazone—ALB—Selenium Micronutrient Network—IL6—psoriasis	1.9e-05	0.000605	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—CARM1—psoriasis	1.87e-05	0.000593	CbGpPWpGaD
Rosiglitazone—PPARG—Gene Expression—VDR—psoriasis	1.82e-05	0.000579	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—CYP2S1—psoriasis	1.81e-05	0.000573	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—NDUFA5—psoriasis	1.8e-05	0.000571	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—CYP2S1—psoriasis	1.79e-05	0.000568	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.78e-05	0.000566	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.75e-05	0.000555	CbGpPWpGaD
Rosiglitazone—PPARG—Developmental Biology—NFKB1—psoriasis	1.7e-05	0.000538	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.68e-05	0.000532	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—CARM1—psoriasis	1.66e-05	0.000528	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—CARM1—psoriasis	1.57e-05	0.000499	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.55e-05	0.000493	CbGpPWpGaD
Rosiglitazone—PPARG—Developmental Biology—VEGFA—psoriasis	1.54e-05	0.000489	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—CYP2S1—psoriasis	1.53e-05	0.000486	CbGpPWpGaD
Rosiglitazone—PPARG—Developmental Biology—STAT3—psoriasis	1.52e-05	0.000484	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism—CAT—psoriasis	1.46e-05	0.000463	CbGpPWpGaD
Rosiglitazone—PPARG—Developmental Biology—TNF—psoriasis	1.32e-05	0.000419	CbGpPWpGaD
Rosiglitazone—ALB—Platelet activation, signaling and aggregation—VEGFA—psoriasis	1.32e-05	0.000418	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—NOS2—psoriasis	1.17e-05	0.000372	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.15e-05	0.000366	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—CAT—psoriasis	1.15e-05	0.000365	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.15e-05	0.000364	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism—APOE—psoriasis	1.13e-05	0.00036	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—CARM1—psoriasis	1.07e-05	0.000341	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—CARM1—psoriasis	1.07e-05	0.000339	CbGpPWpGaD
Rosiglitazone—PPARG—Developmental Biology—IL6—psoriasis	1.06e-05	0.000338	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.03e-05	0.000327	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—CAT—psoriasis	1.02e-05	0.000325	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1e-05	0.000319	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism of lipids and lipoproteins—PPARG—psoriasis	9.98e-06	0.000317	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—CAT—psoriasis	9.67e-06	0.000307	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—CARM1—psoriasis	9.59e-06	0.000304	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	9.38e-06	0.000298	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	8.96e-06	0.000284	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—APOE—psoriasis	8.94e-06	0.000284	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—CARM1—psoriasis	8.82e-06	0.00028	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—CARM1—psoriasis	8.74e-06	0.000278	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	8.17e-06	0.000259	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	8.02e-06	0.000254	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—APOE—psoriasis	7.95e-06	0.000252	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—PPARG—psoriasis	7.78e-06	0.000247	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—APOE—psoriasis	7.52e-06	0.000239	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—CARM1—psoriasis	7.47e-06	0.000237	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	6.98e-06	0.000222	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—PPARG—psoriasis	6.92e-06	0.00022	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—VEGFA—psoriasis	6.8e-06	0.000216	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—CAT—psoriasis	6.61e-06	0.00021	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—CAT—psoriasis	6.57e-06	0.000209	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—PPARG—psoriasis	6.55e-06	0.000208	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—CAT—psoriasis	5.9e-06	0.000187	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—CAT—psoriasis	5.42e-06	0.000172	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—CAT—psoriasis	5.38e-06	0.000171	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—TP53—psoriasis	5.14e-06	0.000163	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—APOE—psoriasis	5.13e-06	0.000163	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—APOE—psoriasis	5.11e-06	0.000162	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—CAT—psoriasis	4.6e-06	0.000146	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—APOE—psoriasis	4.58e-06	0.000145	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—PPARG—psoriasis	4.47e-06	0.000142	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—PPARG—psoriasis	4.45e-06	0.000141	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—APOE—psoriasis	4.22e-06	0.000134	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—APOE—psoriasis	4.18e-06	0.000133	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—PPARG—psoriasis	3.99e-06	0.000127	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—PPARG—psoriasis	3.67e-06	0.000117	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—PPARG—psoriasis	3.64e-06	0.000116	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—APOE—psoriasis	3.57e-06	0.000113	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—PPARG—psoriasis	3.11e-06	9.87e-05	CbGpPWpGaD
